



## Ind-Swift LABORATORIES LIMITED

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101  
Phones : ++ 91 - 172-2730503, 2730920, 5061850, 5061853  
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com  
CIN No. L24232CH1995PLC015553



Ref: ISLL:CH:2025

Date: 25<sup>th</sup> July 2025

**The President**  
**Corporate Relationship Department**  
**BSE Limited**  
**Phiroze Jeejeebhoy Towers,**  
**25<sup>th</sup> Floor, Dalal Street,**  
**Mumbai 400 001**

**The Vice President,**  
**Listing Compliance Department,**  
**National Stock Exchange of India Limited,**  
**Exchange Plaza, 5<sup>th</sup> Floor**  
**Plot No. C/2, G-Block,**  
**Bandra Kurla Complex, Bandra (E),**  
**Mumbai 400 051**

**BSE Scrip Code: 532305**

**NSE Symbol: INDSWFTLAB**

**SUB: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir/Ma'am,

We have received attached intimation under Regulation 7(2) read with Regulation 6(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015 and under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 from M/s. Essix Biosciences Limited, regarding acquisition of 7,00,000 equity shares upon conversion of equivalent numbers of warrants into equity on 24<sup>th</sup> July 2025.

We request you to treat this intimation as compliance with the aforesaid regulations and take the same on record.

For IND-SWIFT LABORATORIES LTD.



**PARDEEP VERMA**  
**VP-CORPORATE AFFAIRS &**  
**COMPANY SECRETARY**

Encl: a/a

# Essix Biosciences Limited

Regd. Off. : SCO 850, Shivalik Enclave, NAC Manimajra, Chandigarh - 160101 (INDIA)  
Phone : +91-172-2730503, 2730920, Fax : +91-172-2730504, 2736294  
Place of Business: Village Bhabat, Zirakpur Ambala Highway, Zirakpur, Mohali- Punjab (India)  
Ph. +91-9317812731, CIN NO. U74999CH1993PLC033428

Date: July 23, 2025

To,

**Company Secretary & Compliance Officer**  
**Ind- Swift Laboratories Limited**  
SCO:850, Shivalik Enclave, NAC,  
Manimajra, Chandigarh -160101, India

**Subject: Submission of disclosure under Regulation 7(2)(a) read with Regulation 6(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015.**


Dear Sir/Madam,


With reference to the above-captioned subject, please note that I, Himanshu Jain, on behalf of Essix Biosciences Limited, Promoter of Ind- Swift Laboratories Limited ('the Company') have acquired 7,00,000 Equity Shares pursuant to the conversion of fully convertible warrants of the Company having face value of Rs. 10/- each representing 0.97% of the post allotment paid-up equity share capital of the Company on July 21, 2025, on a preferential basis.

In reference to the above, kindly find enclosed herewith the disclosure required under Regulation 7(2)(a) read with Regulation 6(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015.

Kindly take the above information on your records.

For Essix Biosciences Limited

  
**Himanshu Jain**  
**Director**  
**DIN: 00014533**



# Essix Biosciences Limited

Regd. Off. : SCO 850, Shivalik Enclave, NAC Manimajra, Chandigarh - 160101 (INDIA)  
Phone : +91-172-2730503, 2730920, Fax : +91-172-2730504, 2736294  
Place of Business: Village Bhabat, Zirakpur Ambala Highway, Zirakpur, Mohali- Punjab (India)  
Ph. +91-9317812731, CIN NO. U74999CH1993PLC033428

**Date: July 23, 2025**

To,  
The Listing Compliance Department  
**National Stock Exchange of India Limited,**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (East), Mumbai - 400051

To,  
The Listing Compliance Department,  
**BSE Limited**  
P. J. Tower, Dalal Street  
Mumbai – 400 001

**Symbol: INDSWFTLAB**

**Scrip Code: 532305**

**Subject : Disclosure under Regulation 29(2) of the Securities and Exchange Board of India  
(Substantial Acquisition of Shares and Takeovers) Regulations, 2011.**

**Dear Sir/ Madam,**

With reference to the captioned note that I, Himanshu Jain, on behalf of Essix Biosciences Limited (“Acquirer”), Promoter of Ind- Swift Laboratories Limited (“Target Company”) along with N.R. Munjal, Annie Mehta, Bhanavi Mehta, Divya Munjal, Gopal Munjal, Himanshu Jain, Ishav Mehta, Meenakshi Mehta, Neera Mehta, Neeta Munjal, Nidhi Munjal, Ravi Mehta, Rishav Mehta, S. R. Mehta, Sahil Munjal, Sunita Jain, V.R. Mehta, IND Swift Limited (hereinafter collectively referred to as “PACs”), wish to inform your good office that the Acquirer, has acquired 18,00,000 (Eighteen Lakh) Equity Shares pursuant to the conversion of Fully Convertible Warrants having face value of Rs. 10/- each of the Target Company on July 02, 2025, and July 21, 2025 into Equity Shares.

In this regard, please find enclosed the disclosure under Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.


You are requested to take the same on records.

**Thanking You.**

**Yours Faithfully,**

**For Essix Biosciences Limited**

  
**Himanshu Jain**  
**Director**  
**DIN: 00014533**



**Date: July 23, 2025**

**Place: Chandigarh**

**CC:**

**The Board of Directors**

**Ind- Swift Laboratories Limited**

**SCO:850, Shivalik Enclave, NAC, Manimajra, Chandigarh-160101, India.**

# Essix Biosciences Limited

Regd. Off. : SCO 850, Shivalik Enclave, NAC Manimajra, Chandigarh - 160101 (INDIA)

Phone : +91-172-2730503, 2730920, Fax : +91-172-2730504, 2736294


Place of Business: Village Bhabat, Zirakpur Ambala Highway, Zirakpur, Mohali- Punjab (India)

Ph. +91-9317812731, CIN NO. U74999CH1993PLC033428

## Disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers)

### Regulations, 2011

Name of the Target Company (TC)	<b>Ind- Swift Laboratories Limited</b>		
Names of the Acquirer and Persons Acting in Concert (PAC) with the Acquirer	Essix Biosciences Limited ("Acquirer")  1. N.R. Munjal 2. Annie Mehta 3. Bhanavi Mehta 4. Divya Munjal 5. Gopal Munjal 6. Himanshu Jain 7. Ishav Mehta 8. Meenakshi Mehta 9. Neera Mehta 10. Necta Munjal 11. Nidhi Munjal 12. Ravi Mehta 13. Rishav Mehta 14. S. R. Mehta 15. Sahil Munjal 16. Sunita Jain 17. V.R. Mehta 18. IND Swift Limited (Collectively referred to as "PACs")		
Whether the Acquirer belongs to Promoter/Promoter group	Yes		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	1. National Stock Exchange of India Limited ("NSE") and 2. BSE Limited ("BSE")		
<b>Details of the acquisition as follows</b>	<b>Number</b>	<b>% w.r.t. total Share/voting capital wherever applicable</b>	<b>% w.r.t. total diluted Share/voting capital of the TC</b>
<b>Before the acquisition/disposal under consideration, holding of:</b>			
a. Shares carrying voting rights:			
Acquirer	2,23,27,507	37.79	26.24
PAC's	24,91,276	4.22	2.93
b. Shares in the nature of encumbrance (pledge/ lien/non-disposal undertaking/ others)	Nil	NA	NA



# Essix Biosciences Limited


Regd. Off. : SCO 850, Shivalik Enclave, NAC Manimajra, Chandigarh - 160101 (INDIA)

Phone : +91-172-2730503, 2730920; Fax : +91-172-2730504, 2736294

Place of Business: Village Bhabat, Zirakpur Ambala Highway, Zirakpur, Mohali- Punjab (India)

Ph. +91-9317812731, CIN NO. U74999CH1993PLC033428

c. Voting rights (VR) otherwise than by equity shares	Nil	NA	NA
d. Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category):	Nil	NA	NA
Acquirer	80,00,000	-	9.40
<b>e. Total (a+b+c+d)</b>	<b>3,28,18,783</b>	<b>42.00</b>	<b>38.57</b>
<b>Details of acquisition</b>			
a. Shares carrying voting rights acquired/sold:			
Acquirer	18,00,000	2.49	2.12
b. VRs acquired /sold otherwise than by shares	Nil	NA	NA
c. Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold:	Nil	NA	NA
d. Shares encumbered/invoked/released by the acquirer	Nil	NA	NA
<b>e. Total (a+b+c+d)</b>	<b>18,00,000</b>	<b>2.49</b>	<b>2.12</b>
<b>After the acquisition, holding of:</b>			
a. Shares carrying voting rights:			
Acquirer	2,41,27,507	33.33	28.36
PACs	24,91,276	3.44	2.93
b. Shares encumbered with the acquirer	Nil	NA	NA
c. VRs otherwise than by equity shares	Nil	NA	NA
d. Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition:			
Acquirer	62,00,000	-	7.29
<b>e. Total (a+b+c+d)</b>	<b>3,28,18,783</b>	<b>36.77</b>	<b>38.57</b>
Mode of acquisition (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc.)	<b>Preferential Allotment</b> (Equity Shares allotted pursuant to the conversion of Fully Convertible Warrants)		
Date of receipt of intimation of allotment of shares, whichever is applicable	<b>July 02, 2025 and July 23, 2025 ("Date of Allotment")</b>		
Equity share capital / total voting capital of the TC before the said acquisition	Rs. 59,08,68,600 divided into 5,90,86,860 Equity Shares of face value of Rs. 10/- each as on date of allotment of warrants i.e. 30 <sup>th</sup> August 2024.		



# Essix Biosciences Limited

Regd. Off. : SCO 850, Shivalik Enclave, NAC Manimajra, Chandigarh - 160101 (INDIA)


Phone : +91-172-2730503, 2730920, Fax : +91-172-2730504, 2736294


Place of Business: Village Bhabat, Zirakpur Ambala Highway, Zirakpur, Mohali- Punjab (India)

Ph. +91-9317812731, CIN NO. U74999CH1993PLC033428

Equity share capital/ total voting capital of the TC after the said acquisition	Rs. 72,38,68,600 divided into 7,23,86,860 Equity Shares of face value of Rs. 10/- each.
Total diluted share/voting capital of the TC after the said acquisition	Rs. 85,08,68,600 divided into 8,50,86,860 Equity Shares of face value of Rs. 10/- each.

For Essix Biosciences Limited

  
Himanshu Jain  
Director  
DIN: 00014533



Place: Chandigarh

Date: July 23, 2025